Citigroup Inc. bought 892,799 shares of HENGRUI PHARMA (01276) off-exchange at an average of HKD 48.2397 per share on October 5, 2026, involving about HKD 43.07 million. This off-exchange transaction was executed with cash consideration, not matched on the SEHK open market, and therefore not a direct secondary-market dealing. Additionally, Citigroup Inc.'s short position in HENGRUI PHARMA increased from 2.52% to 2.87%, representing 7.42 million shares.
Prior to the acquisition, Citigroup Inc.'s long position in HENGRUI PHARMA was 12.65 million shares, representing 4.89%; following the acquisition, the holding changed to 13.54 million shares, with the long position ratio rising to 5.24%. For the short position, prior holdings were 6.52 million shares, 2.52%; after the event, holdings stood at 7.42 million shares, 2.87%.